Hence, a combined treatment of MET, EGFR, and PI3K inhibitors may be an effective therapeutic strategy in patients with capmatinib-resistant NSCLC (Ji et al., 2015). This evidence concerns the gene EGFR and non-small cell lung carcinoma.